Suppr超能文献

尿血管紧张素原除影像学分类外,还可预测常染色体显性遗传性多囊肾病的肾脏结局。

Urinary Angiotensinogen in addition to Imaging Classification in the Prediction of Renal Outcome in Autosomal Dominant Polycystic Kidney Disease.

机构信息

Department of Internal Medicine, Hallym University College of Medicine, Seoul, Korea.

Hallym University Kidney Research Institute, Seoul, Korea.

出版信息

J Korean Med Sci. 2020 Jun 8;35(22):e165. doi: 10.3346/jkms.2020.35.e165.

Abstract

BACKGROUND

Intrarenal renin-angiotensin system (RAS) is known to play the major role in the development of hypertension and renal progression in autosomal dominant polycystic kidney disease (ADPKD). Urinary angiotensinogen to creatinine ratio (AGT/Cr) was suggested as a novel biomarker to reflect intrarenal RAS activity. This study was performed to evaluate urinary AGT/Cr as a predictive biomarker for renal function decline in addition to imaging classification in a prospective ADPKD cohort.

METHODS

From 2011 to 2016, a total of 364 ADPKD patients were enrolled in the prospective cohort called the KoreaN Cohort Study for Outcomes in Patients With Chronic Kidney Disease (KNOW-CKD). Among them, a total of 207 subjects in chronic kidney disease stage 1-4 with baseline urinary AGT and total kidney volume and subsequent renal function follow-up data over more than 1 year were included in the analysis. Patients were defined as slow progressors (SP) if they are classified as 1A or 1B by imaging classification whereas rapid progressors (RP) if they are classified as 1C-1E. Patients were divided according to AGT/Cr quartiles and annual estimated glomerular filtration rate (eGFR) slope was compared among highest quartile (hAGT group) and the rest of quartiles (lAGT group). Patients were divided into 4 groups to evaluate the predictive value of urinary AGT/Cr in addition to imaging classification: SP/lAGT, SP/hAGT, RP/lAGT, and RP/hAGT. The Cox regression model was used to evaluate the hazard ratio (HR) between groups.

RESULTS

The mean age was 45.9 years and 88.9% had hypertension. Baseline eGFR was 79.0 ± 28.4 mL/min/1.73 m² and median height-adjusted total kidney volume was 788.2 (471.2; 1,205.2) mL/m. The patients in the hAGT group showed lower eGFR (72.4 ± 24.8 vs. 81.1 ± 29.2 mL/min/1.73 m², = 0.039), lower plasma hemoglobin (13.0 ± 1.4 vs. 13.7 ± 1.6 g/dL, = 0.007), higher urinary protein to creatinine ratio (0.14 [0.09, 0.38] vs. 0.07 [0.04, 0.12] g/g, = 0.007) compared to the lAGT group. The hAGT group was an independent risk factor for faster eGFR decline after adjusting for gender, RP, baseline eGFR, and other known risk factors. During median follow-up duration of 4.6 years, a total of 29 renal events (14.0%) occurred. The SP/hAGT group showed significantly higher risk of developing renal outcome compared to SP/lAGT group (HR, 13.4; 95% confidence interval, 1.282-139.324; = 0.03).

CONCLUSION

Urinary AGT/Cr can be a useful predictive marker in the patients with relatively small ADPKD. Various biomarkers should be considered to define RP when implementing novel treatment in the patients with ADPKD.

摘要

背景

肾内肾素-血管紧张素系统(RAS)被认为在常染色体显性多囊肾病(ADPKD)中高血压和肾脏进展的发展中起主要作用。尿血管紧张素原与肌酐比值(AGT/Cr)被认为是反映肾内 RAS 活性的新型生物标志物。本研究旨在评估尿 AGT/Cr 作为预测生物标志物,除了影像学分类外,还可用于预测前瞻性 ADPKD 队列中肾功能下降。

方法

2011 年至 2016 年,共有 364 名 ADPKD 患者被纳入名为韩国慢性肾脏病患者结局研究的前瞻性队列(KNOW-CKD)。其中,共有 207 名慢性肾脏病 1-4 期的患者,基线时具有尿 AGT 和总肾体积,并且在 1 年以上的时间内进行了后续肾功能随访数据,被纳入分析。如果患者通过影像学分类被分类为 1A 或 1B,则被定义为缓慢进展者(SP),如果他们被分类为 1C-1E,则被定义为快速进展者(RP)。根据 AGT/Cr 四分位数将患者分为最高四分位数(hAGT 组)和其余四分位数(lAGT 组),并比较两组间每年估算肾小球滤过率(eGFR)斜率。将患者分为 4 组,以评估尿 AGT/Cr 除影像学分类外的预测价值:SP/lAGT、SP/hAGT、RP/lAGT 和 RP/hAGT。使用 Cox 回归模型评估组间的危险比(HR)。

结果

患者的平均年龄为 45.9 岁,88.9%患有高血压。基线时 eGFR 为 79.0 ± 28.4 mL/min/1.73 m²,身高调整后的总肾体积中位数为 788.2(471.2;1205.2)mL/m。hAGT 组患者的 eGFR 更低(72.4 ± 24.8 与 81.1 ± 29.2 mL/min/1.73 m², = 0.039),血浆血红蛋白水平更低(13.0 ± 1.4 与 13.7 ± 1.6 g/dL, = 0.007),尿蛋白与肌酐比值更高(0.14[0.09,0.38]与 0.07[0.04,0.12] g/g, = 0.007),与 lAGT 组相比。在调整性别、RP、基线 eGFR 和其他已知危险因素后,hAGT 组是 eGFR 下降更快的独立危险因素。在中位随访 4.6 年期间,共发生 29 例肾脏事件(14.0%)。与 SP/lAGT 组相比,SP/hAGT 组发生肾脏结局的风险明显更高(HR,13.4;95%置信区间,1.282-139.324; = 0.03)。

结论

尿 AGT/Cr 可作为 ADPKD 患者相对较小的预测生物标志物。在 ADPKD 患者中实施新的治疗方法时,应考虑各种生物标志物来定义 RP。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bd19/7279941/c041dad5f62f/jkms-35-e165-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验